Literature DB >> 13862376

Hodgkin's disease, carcinoma of the breast, and other tumors treated with vinblastine sulfate.

J G ARMSTRONG, R W DYKE, P J FOUTS, J E GAHIMER.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS/therapy; BREAST NEOPLASMS/therapy; HODGKIN'S DISEASE/therapy; NEOPLASMS/therapy

Mesh：

Substances：

Year:  1962        PMID： 13862376

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  8 in total

1.  Chemotherapy of Hodgkin's Disease with Cyclophosphamide, Vinblastine, and Procarbazine.

Authors:  G H Fairley; M J Patterson; R B Scott
Journal:  Br Med J       Date:  1966-07-09

2.  [Multipolar effect of vinblastine on cell division in Allium cepa L].

Authors:  J P Hervás
Journal:  Experientia       Date:  1975-02-15

3.  Phase II study of divided-dose vinblastine in advanced breast cancer patients.

Authors:  G Giaccone; M Bagatella; O Bertetto; M Donadio; A Calciati
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  [Electron microscopy studies on brain and spinal ganglia of mice fetuses (day 12-17) after application of vincristine].

Authors:  W Noack
Journal:  Acta Neuropathol       Date:  1972       Impact factor: 17.088

5.  Improved tolerance of vincristine by glutamic acid. A preliminary report.

Authors:  D V Jackson; E K Pope; L D Case; H B Wells; D R White; M R Cooper; R D Caldwell; W R Black; H B Muss; J M Cruz
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

Review 6.  Chemotherapy of advanced non-small cell lung cancer. A review.

Authors:  B J Takasugi; T P Miller
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

7.  [Long term treatment of advanced lymphogranulomatosis with vinblastine sulfate].

Authors:  E Schulz; W Jüngling; K Hausmann
Journal:  Klin Wochenschr       Date:  1969-02-15

Review 8.  Cancer chemotherapy: past, present, and future--Part I.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1984-08       Impact factor: 1.798
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.